Zai Lab Analyst Ratings
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Gilead Upgraded to Outperform by Leerink on PreEP Outlook
Peering Into Gilead Sciences's Recent Short Interest
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Travere Therapeutics Analyst Ratings
US stock market outlook: Chinese assets collectively rise before the market! YINN surged more than 15%, bilibili rose more than 7%; Goldman Sachs: debt conversion is the first step in China's fiscal big move, which will stimulate economic growth.
Trump claimed to have received a 'plea for help' call from Cook, involving Apple being fined heavily by the European Union; Is there still an 'undercurrent' behind the bull market of US stocks? Goldman Sachs: The rise of the US dollar is a major threat; The gold price continues to hit new highs! As risk aversion heats up, spot gold rises above $2,700.
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Central Bank's major announcement! Reserve ratio cut, interest rate cut, officially launching share buyback and shareholding refinancing.
Pan Gongsheng stated that it is expected to carefully assess the market liquidity situation before the end of the year, and opportunistically further lower the deposit reserve ratio by 0.25-0.5 percentage points; reduce the open market 7-day reverse repurchase operation rate by 0.2 percentage points.
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
12 Health Care Stocks Moving In Thursday's After-Market Session
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Novocure Gets FDA Approval for Its Lung Cancer Treatment
Travere Therapeutics To Present 11 Abstracts, Including One Late-breaking Abstract At Upcoming American Society Of Nephrology Kidney Week 2024 In San Diego, October 23-27
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Key Takeaways From ADMA Biologics Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter